Septerna to Participate in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Septerna (Nasdaq: SEPN) announced that management will participate in two investor events in September 2026: the Wells Fargo 21st Annual Healthcare Conference with a fireside chat on September 8, 2026, at 8:00 a.m. ET, and the Cantor Global Healthcare Conference 2026 with a fireside chat on September 10, 2026, at 11:30 a.m. ET. Live webcasts and 30-day archives will be accessible via the investors section of the company’s website.
Details
News Market Reaction – SEPN
On Sep 1, the day this news came out, SEPN closed 1.23% below the previous close.
Data tracked by StockTitan Argus for the Sep 1 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following investor conferences in September:
Wells Fargo 21st Annual Healthcare Conference
Fireside chat on Tuesday, September 8, 2026, at 8:00 a.m. ET
Cantor Global Healthcare Conference 2026
Fireside chat on Thursday, September 10, 2026, at 11:30 a.m. ET
A live webcast of each presentation will be available in the investors section of the company’s website at www.septerna.com. The webcasts will be archived for at least 30 days following the presentation.
About Septerna
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform® is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.
Investor Contact:
Renee Leck, THRUST
renee@thrustsc.com
Media Contact:
Carly Scaduto, THRUST
carly@thrustsc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.